PMID- 37258954
OWN - NLM
STAT- MEDLINE
DCOM- 20231128
LR  - 20240515
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 30
IP  - 6
DP  - 2023 Dec
TI  - Meta-analysis of the effectiveness of heparin in suppressing physiological 
      myocardial FDG uptake in PET/CT.
PG  - 2454-2463
LID - 10.1007/s12350-023-03296-2 [doi]
AB  - BACKGROUND: The present meta-analysis aims to investigate the effectiveness of 
      heparin administration in suppressing physiological myocardial 
      (18)F-fluorodeoxyglucose (FDG) uptake on positron emission tomography 
      (PET)/computed tomography (CT), as its role in this regard has not been well 
      investigated. METHODS: PRISMA guidelines were used to interrogate the PubMed, 
      Embase, Cochrane library, Web of Knowledge, and www.clinicaltrail.gov databases 
      from the earliest records to March 2023. The final analysis included five 
      randomized controlled trials (RCTs). Meta-analysis was conducted to compare the 
      effectiveness of unfractionated heparin (UFH) administration versus non-UFH 
      administration, and subgroup analysis based on fixed and variable fasting 
      durations was conducted. Effect sizes were pooled using a random-effects model, 
      and the pooled odds ratios (ORs) were calculated. RESULTS: Five eligible RCTs 
      with a total of 910 patients (550 with heparin, 360 without heparin) were 
      included. The forest plot analysis initially indicated no significant difference 
      in the suppression of myocardial FDG uptake between the UFH and non-UFH groups 
      (OR 2.279, 95% CI 0.593 to  8.755, p = 0.23), with a high degree of statistical 
      heterogeneity (I(2) = 91.16%). Further subgroup analysis showed that the fixed 
      fasting duration group with UFH administration had statistically significant 
      suppression of myocardial FDG uptake (OR 4.452, 95% CI 1.221 to 16.233, 
      p = 0.024), while the varying fasting duration group did not show a significant 
      effect. CONCLUSIONS: According to the findings of our meta-analysis, we suggest 
      that intravenous administration of UFH can be considered as a supplementary 
      approach to suppress myocardial FDG uptake.
CI  - (c) 2023. The Author(s) under exclusive licence to American Society of Nuclear 
      Cardiology.
FAU - Chan, Shan-Ho
AU  - Chan SH
AD  - Department of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine 
      and Management, Kaohsiung, Taiwan.
FAU - Huang, Cheng-Kai
AU  - Huang CK
AD  - Department of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine 
      and Management, Kaohsiung, Taiwan.
AD  - Department of Nuclear Medicine, Cheng-Ching General Hospital, Chung-Kang Branch, 
      Taichung, Taiwan.
FAU - Luzhbin, Dmytro
AU  - Luzhbin D
AD  - Institute of Statistical Science, Academia Sinica, Taipei, Taiwan.
FAU - Hou, Po-Nien
AU  - Hou PN
AD  - Department of Nuclear Medicine, Chang-Bing Show Chwan Memorial Hospital, 
      Changhua, Taiwan.
FAU - Chang, Yu-Ting
AU  - Chang YT
AD  - Department of Biomedical Imaging and Radiological Sciences, National Yang Ming 
      Chiao Tung University, No.155, Sec.2, Linong Street, Taipei, 11221, Taiwan.
FAU - Wu, Jay
AU  - Wu J
AD  - Department of Biomedical Imaging and Radiological Sciences, National Yang Ming 
      Chiao Tung University, No.155, Sec.2, Linong Street, Taipei, 11221, Taiwan. 
      jaywu@nycu.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230531
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of 
      Nuclear Cardiology
JID - 9423534
RN  - 9005-49-6 (Heparin)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Humans
MH  - *Heparin
MH  - *Fluorodeoxyglucose F18
MH  - Positron Emission Tomography Computed Tomography/methods
MH  - Myocardium
MH  - Administration, Intravenous
MH  - Positron-Emission Tomography/methods
MH  - Radiopharmaceuticals
OTO - NOTNLM
OT  - FDG
OT  - PET/CT
OT  - myocardial FDG uptake
OT  - unfractionated heparin
EDAT- 2023/06/01 01:08
MHDA- 2023/11/28 06:42
CRDT- 2023/05/31 23:33
PHST- 2023/03/17 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/11/28 06:42 [medline]
PHST- 2023/06/01 01:08 [pubmed]
PHST- 2023/05/31 23:33 [entrez]
AID - S1071-3581(24)00187-9 [pii]
AID - 10.1007/s12350-023-03296-2 [doi]
PST - ppublish
SO  - J Nucl Cardiol. 2023 Dec;30(6):2454-2463. doi: 10.1007/s12350-023-03296-2. Epub 
      2023 May 31.